Updated:
Yantai Luye Pharmaceutical Holdings
Yantai Luye Pharmaceutical Holdings (Group) is a corporate investor based in Yantai, China. It manages approximately $3.9 billion in assets across two funds,...
Yantai Luye Pharmaceutical Holdings
Yantai Luye Pharmaceutical Holdings (Group) is a corporate investor based in Yantai, China. It manages approximately $3.9 billion in assets across two funds, primarily focused on Asia.
General information
Firm type
Corporate Investor
Year founded
1994
Location
Region
Asia
Country
China
City
Yantai
Corporate office
Yantai, Shandong, China
Additional offices
Shanghai, China · Shenzhen, China
Principals
Liu Dianbo
Executive Chairman and Founder, Luye Life Sciences Group
Yuan Huixian
Executive Director and Founding Member
Yang Rongbing
Vice Executive Chairman and Founding Member
Sector focus
Frequently asked questions
Who controls investment decisions at Yantai Luye Pharmaceutical Holdings?
Strategic and investment decisions are concentrated with founder and Executive Chairman Liu Dianbo, alongside founding members Yuan Huixian and Yang Rongbing. The group operates as a closely held corporate investor with no external limited partners, meaning the founding trio controls both the pharmaceutical operating business and the allocation of its cash flows into real estate, healthcare infrastructure, and other assets.
How does the holding group relate to the publicly traded Luye Pharma Group?
Yantai Luye Pharmaceutical Holdings is the private parent and controlling shareholder of Luye Pharma Group, which listed on the Hong Kong Stock Exchange in 2014. The holding company retains the pharmaceutical dividends and directs them into private investments, while Luye Pharma remains the core operating business with manufacturing plants across China and international licensing partnerships, including with AstraZeneca.
What does the group's real estate portfolio consist of?
The portfolio is concentrated in Yantai, Shandong province, and includes Pula Valley, a mixed-use winery and chateau development, and Jiaodong Culture Square, a commercial complex that houses a theater and Yantai Urban Art Gallery. The group also holds commercial assets in Shanghai and Shenzhen tied to its healthcare operations, and the Pula Valley wine collection represents an additional investment in luxury hospitality and lifestyle.
What is the nature of the collaboration with Cleveland Clinic?
The group is developing the Shanghai New Hongqiao International Medical Center in partnership with Cleveland Clinic, one of the most recognized US hospital brands. This represents a major capital commitment to premium private healthcare delivery in China, leveraging Cleveland Clinic's clinical protocols and brand while Yantai Luye provides the real estate and local operating infrastructure.
Does the group invest in sectors outside healthcare and real estate?
Publicly confirmed investments are concentrated in pharmaceutical manufacturing, private healthcare services, and real estate. The Pula Valley winery and wine collection represent a hospitality and lifestyle allocation, but there is no evidence of venture capital, technology, or financial-sector investing by the holding group. Its posture remains anchored to operating assets adjacent to its pharmaceutical core.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: